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A 27 year old female with Graves’ disease presented with fever, exertional dyspnea and polyarthralgia. Erythema
nodosum had occured three months earlier. The patient declared irregular use of propylthiouracil (PTU) for the last
8 months. Neutropenia and microscopic hematuria developed in the second week of admission. Chest X-ray
showed inhomogenous pulmonary opacities, left pleural effusion and cardiomegaly. Computed tomography (CT)
revealed multiple subpleural nodules, left pleural effusion, pericardial effusion, enlarged mediastinal and axillary
lymph nodes. Bronchoalveolar lavage (BAL) cytology demonstrated hemosiderin laden macrophages.
Histopathologic examination of the transbronchial biopsy specimen revealed a nonspecific inflammation. Serum
was positive for ANA, P-ANCA, MPO-ANCA, PR3-ANCA and negative for anti-ds-DNA, C-ANCA, C3, C4 and anti-
histone antibody. All symptoms resolved in two months after PTU withdrawal and starting steroid treatment. The
same clinical manifestations recurred when the patient used PTU erronously one month after discharge.
This is a case of PTU induced-autoimmune disease in whom the accurate distinction between drug-induced-lupus
(DIL) and vasculitis was not possible due to the significant overlap of clinical and laboratory findings causing a
significant diagnostic challenge for the chest physician.
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PTU can cause adverse reactions including fever, rash,
leucopenia, arthiritis, vasculitis and lupus-like syndrome
[1]. However, pulmonary complications like interstitial
pneumonia, adult respiratory distress-like syndrome and
pleural effusion are extremely rare [2,3] The mortality
rate is low and related to systemic manifestations. PTU-
induced lupus is now well established and many other
autoimmune disorders including vasculitis have been
reported. Most of the cases of PTU-induced auto-
immune phenomena are due to vasculitis.
We present the case of a patient who developed ery-
thema nodosum, pericardial and pleural effusion, sub-
pleural nodules, microhematuria, alveolar hemorrhage,
mediastinal and axillary lymph node enlargement due to
PTU treatment. Although there are significant differences
in the clinical features of drug-induced lupus (DIL) and
vasculitis that allow an accurate diagnosis, the distinction* Correspondence: tetikkurt@gmail.com
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reproduction in any medium, provided the orwas not possible in our case because of substantial overlap
of clinical findings.Case presentation
A 27 year old woman with a history of Graves’ disease
was admitted for fever, exertional dyspnea and polyar-
thralgia. She had started on PTU (150 mg p.oqd) for
Graves’ disease which she had used irregularly during
the last 8 months. There was no other past medical his-
tory of interest.
Four weeks before admission the patient developed
low grade fever (37.6°C), dry cough, exertional dyspnea,
polyarthralgia and left sided pleural pain. Erythema
nodosum had occured three months earlier. WBC was
3.26 × 103/ml with 59 percent neutrophils, CRP: 155,
ERS: 74 mm/h. Blood biochemistry was within normal
limits. Urine analysis revealed 10 to 12 red cells per low
power field and mild proteinuria. ECG revealed sinus
tachycardia (112/min). There was no radiologic abnor-
malitiy on joint films. Chest x-ray showed cardiomegaly,
left pleural effusion and bilateral inhomogenous opaci-
ties. Tuberculin test was negative. Arterial blood gases;l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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function tests were normal. Chest CT showed pericardial
and left pleural effusion, bilateral subpleural nodules, left
basal ground glass pattern (Figure 1), multiple medias-
tinal and bilateral axillary lymph nodes. Serum D-dimer
was 4.57 mg/L. Doppler ultrasonography of the legs was
normal. She was given a course of antibiotics for seven
days with no improvement of her symptoms.
Serologic tests, including rheumatoid factor, anti-
double-stranded deoxyribonucleic acid, complement
levels, antiglomerular basal membrane antibody, and
Brucella agglutination test were negative. Serum anti-
nuclear antibodies (ANA: +, homogeneous), perinuclear
anti-neutrophil cytoplasmic antibodies (P-ANCA: +),
cytoplasmic anti-neutrophil cytoplasmic antibodies (C-
ANCA: +), antimyeloperoxidase antibodies (MPO-
ANCA: 135.4 EU/ml), and antiproteinase 3 antibodies
(PR3-ANCA: 27.8 EU/ml) were positive. The level of
anti-thyroperoxidase antibodies (anti-TPO) was high
(242.96 IU/ml). Pleural fluid was an exudate with
lymphocyte predominance (68%). The culture and the
cytologic examination of the pleural fluid was not diag-
nostic. BAL showed hemosiderin-laden macrophages
with a normal differential cell count. Culture of the BAL
fluid was negative for bacteria, tuberculosis and fungus.
Histopathologic examination of the transbronchial speci-
men did not demonstrate any features of vasculitis,
granulomatous changes or fibrosis but only nonspecific
inflammation. Serum anti-histone antibody was negative.
PTU treatment was stopped. Methamizole (30 mg/day)
and methylprednisolone (40 mg/day) were commenced.
Symptoms, laboratory, and radiologic findings com-
pletely resolved within two months of PTU withdrawal
(Figure 2). Identical clinical manifestations, including the
laboratory findings, recurred when the patient errone-
ously used PTU again instead of methamizole for six
weeks after the hospital discharge, when the resolutionFigure 1 Chest CT showing bilateral subpleural nodules and left
basal ground glass pattern.of symptoms had been reached in four weeks after the
discontinuation of the drug. The patient had an unevent-
ful recovery following thyroidectomy.
Discussion
It has long been known that PTU can induce an adverse
autoimmune response with DIL or vasculitis [4]. Cases
can be classified into DIL or vasculitis according to the
accepted definitions, clinical and serological features.
Here we describe the case of a patient who presented
with a clinical picture of vasculitis during PTU treat-
ment for Graves’ disease. Our patient had both findings
of DIL, in relation to the regular long-term medication
use, and vasculitis [5]. After PTU withdrawal, an excel-
lent outcome took place with resolution of all symp-
toms, clinical, laboratory, and radiologic findings,
however the same clinical picture occurred again when
the patient inadvertently used PTU again. The patient
was a diagnostic dilemma for the clinician because the
risk of developing DIL with using PTU is less than 1% of
the treated patients [6]. Moreover the distinction be-
tween DIL and ANCA-associated vasculitis was not pos-
sible because of the significant overlap between these
two entities in our case. Finally the patient did not fit
into any collagen disease profile.
Aloush and coworkers have provided clear distinction
between the DIL and ANCA-associated vasculitis
reviewing their similarities and differences. Patients with
PTU-induced DIL have more musculoskeletal com-
plaints, more serositis and gastrointestinal involvement.
On the contrary, the ANCA-associated vasculitis more
frequently presents upper airways, pulmonary and renal
involvement. ANA, anti-DNA, and anti-histone anti-
bodies are predominantly found in DIL, whereas p-
ANCA are found in a similar proportion of patients in
both groups. c-ANCA are detected only in patients with
vasculitis. All DIL patients recovered completely after
withdrawal of PTU, while about 50% of PTU-inducedFigure 2 Resolution of radiologic findings after PTU withdrawal.
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Nearly every feature of both entities was identified in
our patient with a significant overlap of serologic mar-
kers. DIL includes various manifestations like arthralgia,
pericarditis, pleuritis, and fever, which were all present
in this patient. Antinuclear antibodies are positive in
over 50% of cases and native anti-DNA are reported [8].
These markers were negative in our case. Resolution of
symptoms and radiologic findings after drug withdrawal
suggested strongly the DIL associated with PTU treat-
ment, while negative serum anti-histone antibody with
positive C-ANCA, and the need for steroid immunosu-
pression indicated PTU-induced-vasculitis.
Some patients receiving PTU develop a different and a
more serious kind of adverse autoimmune response
characterized by high titres of antibodies to MPO with
clinical manifestations including pauci-immune necrotiz-
ing and crescentic glomeruloneprithis, upper respiratory
tract disease, and pulmonary hemorrhage with negative
or low titres of ANA [9,10]. Our patient had microhe-
maturia and alveolar hemorrhage that were diagnosed
during the clinical investigation of a possible auto-
immune disorder. Detection of MPO-ANCA with alveo-
lar hemorrhage and microhematuria supports the
presence of alveolar and glomerular vasculitis as Bosch
has suggested [11].
PTU-induced vasculitis often occurs in a few weeks of
treatment but may develop after months or years. The
disorder is not usually dose dependent and may improve
after discontinuation of the drug [12]. The patient was
not compliant and declared very irregular use of PTU in
the previous 8 months when the use of PTU had started.
Antibodies to double-stranded DNA were absent and
complement levels were normal. The high levels of PR3-
ANCA and MPO-ANCA, which is thought to be a spe-
cific marker of anti-thyroid drug-induced vasculitis,
decreased in correlation with the course of symptoms
and the resolution of radiologic findings after PTU
withdrawal.
The mechanism responsible for ANCA and vasculitis
in patients on PTU is not well understood. ANCA pro-
duction may occur as a result of the interaction between
PTU and neutrophils or neutrophil MPO. MPO and
hydrogen peroxide produced by neutrophils can
metabolize the drug leading to the reactive intermediates
that are immunogenic for T-cells and stimulate the im-
mune system [12,13]. The metabolites which have a
cytotoxic activity determine the cell death and produc-
tion of autoantibodies [14]. Because human MPO and
thyroid peroxidase (TPO) are the members of the same
gene family, patients with thyroid disease and TPO anti-
bodies may develop cross-reactivity to MPO. TPO and
MPO antibodies are often both present in these patients
[15] as may be the case for our patient. Serious adverseeffects required corticosteroid treatment. Complete re-
covery of clinical and laboratory findings occured follow-
ing the cessation of PTU and starting of the steroid
treatment. The same clinical picture recurred after the
erroneous use of PTU by the patient.
Regardless of the mechanism, the association between
PTU treatment and ANCA-associated vasculitis or DIL
is rare but well described. Substantial differences in clin-
ical, serologic and outcome of these syndromes provide
an accurate diagnosis [7]. The systemic adverse effects of
PTU may also be difficult to distinguish from the mani-
festations of Graves’ disease or from other vasculitides.
Antineutrophil cytoplasmic antibodies and especially
high levels of anti-histone antibodies are useful for the
diagnosis of PTU associated lupus-like syndrome. It is
important to be aware of this complication because early
withdrawal of the drug results in clinical recovery and
may prevent a fatal outcome.
Our patient had severe respiratory problems with ery-
thema nodosum as the initial sign. Neither the clinical
manifestations and nor the serologic markers of our pa-
tient indicated DIL, ANCA-associated vasculitis or colla-
gen disease accurately. Presence and resolution of
enlarged mediastinal and axillary lymph nodes after drug
withdrawal would also strongly suggest drug induced
autoimmune disease in this case. Different presentations,
overlap syndromes associated with PTU-induced disease,
various clinical and laboratory findings may represent a
diagnostic challenge for the pulmonary clinician. The
current case did not fit into any of the two previously
described classifications.Conclusions
In addition to the negligible incidence of PTU-induced
disease, the overlapping symptoms and laboratory findings
may lead to a diagnostic conflict. Consequently, putting
such patients into the PTU-induced autoimmune disease
classification as opposed to the DIL or ANCA-associated
vasculitis would better describe the clinical features.Consent
Written informed consent was obtained from the patient
for publication of this case report and any accompanying
images. A copy of the written consent is available for re-
view by the Editor-in-Chief of this journal.
Competing interests
The authors declare that they have no competing interests.
Author details
1Pulmonary Diseases Department, Cerrahpasa Medical Faculty, Istanbul
University, Tanzimat sokak Serkan Apt. No 8/16 Caddebostan, Istanbul 34728,
Turkey. 2Internal Medicine Department, Cerrahpasa Medical Faculty, Istanbul
University, Istanbul, Turkey. 3Pathology Department, Bagcılar Training and
Research Hospital, Istanbul, Turkey.
Tetikkurt et al. Multidisciplinary Respiratory Medicine 2012, 7:14 Page 4 of 4
http://www.mrmjournal.com/content/7/1/14Received: 25 June 2012 Accepted: 25 June 2012
Published: 17 July 2012
References
1. Vasily DB, Tyler WB: Propylthiouracil-induced cutaneous vasculitis. Case
presentation and review of the literature. JAMA 1980, 243:458–461.
2. Miyazono K, Okazaki T, Uchida S, Totsuka Y, Matsumoto T, Ogata E,
Terakawa K, Kurihara N, Takeda T: Propylthiouracil-induced diffuse
interstitial pneumonitis. Arch Intern Med 1984, 144:1764–1765.
3. Chevrolet JC, Guelpa G, Schifferli JA: Recurrent adult respiratory
distress–like syndrome associated with propylthiouracil therapy. EurRespir
J 1991, 4:899–901.
4. Yung RL, Richardson BC: Drug-induced lupus. Rheum Dis Clin North Am
1994, 20:61–86.
5. Rubin RL: Drug induced lupus. Toxicology 2005, 209:135–147.
6. Rubin RL: Etiology and mechanisms of drug-induced lupus. Curr Opin
Rheumatol 1999, 11:357–363.
7. Aloush V, Litinsky I, Caspi D, Elkayam O: Propylthiouracil-induced
autoimmune syndromes: two distinct clinical presentations with
different course and management. Semin Arthirits Rheum 2006, 36:4–9.
8. Mathieu E, Fain O, Sitbon M, Thomas M: Systemic adverse effects of
antithyroid drugs. Clin Rheumatol 1999, 18:66–68.
9. Dolman KM, Gans RO, Vervaat TJ, Zevenbergen G, Maingay D, Nikkels RE,
Donker AJ, von dem Borne AE, Goldschmeding R: Vasculitis and
antineutrophil cytoplasmic autoantibodies associated with
prophylthiouracil therapy. Lancet 1993, 342:651–652.
10. D’Cruz D, Chesser AM, Lightowler C, Comer M, Hurst MJ, Baker LR, Raine AE:
Antineutrophil cytoplasmic antibody-positive crescentic
glomerulonephritis associated with anti-thyroid drug treatment. Br J
Rheumatol 1995, 34:1090–1091.
11. Bosch X, López-Soto A, Mirapeix E, Font J, Ingelmo M, Urbano-Márquez A:
Anti-neutrophil cytoplasmic autoantibody-associated alveolar capillaritis
in patients presenting with pulmonary hemorrhage. Arch Pathol Lab Med
1994, 118:517–522.
12. Ohtsuka M, Yamashita Y, Doi M, Hasegawa S: Propylthiouracil-induced
alveolar hemorrhage associated with antineutrophil cytoplasmic
antibody. Eur Respir J 1997, 10:1405–1407.
13. von Schmiedeberg S, Goebel C, Gleichmann E, Uetrecht J: Neutrophils and
drug metabolism. Science 1995, 268:585–586.
14. Cambridge G, Wallace H, Bernstein RM, Leaker B: Autoantibodies to
myeloperoxidase in idiopathic and drug-induced systemic lupus
erithematosus and vasculitis. Br J Rheumatol 1994, 33:109–114.
15. Kimura S, Ikeda-Saito M: Human myeloperoxidase and thyroid peroxidase,
two enzymes with separate and distinct physiological functions, are
evolutionary related members of the same gene family. Proteins 1998,
3:113–120.
doi:10.1186/2049-6958-7-14
Cite this article as: Tetikkurt et al.: Propylthiouracil-induced lupus-like or
vasculitis syndrome. Multidisciplinary Respiratory Medicine 2012 7:14.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
